COMMUNIQUÉS West-GlobeNewswire

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026
27/07/2026
Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 Mont-Saint-Guibert, Belgium – July 27, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), [...]
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
27/07/2026
Management Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and [...]
STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026
27/07/2026
DUBLIN, IRELAND, July 27, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 first quarter results at 9:00 a.m. ET [...]
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
27/07/2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provided an update ahead [...]
Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)
27/07/2026
Company announcement No. 35 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 30, 2026) Copenhagen, Denmark, July 27, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 30 - 2026
27/07/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 20 juillet au 24 juillet 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026
27/07/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 20th July to 24th July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument [...]
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
27/07/2026
Digital subscription platform brings together the Company’s proprietary consumer health products across consumer (B2C) and corporate (B2B) channels Customers can begin through one of three paths: a free nutritionist [...]
Atalante X, Wandercraft’s Self-Balancing Rehabilitation Exoskeleton, Receives ARCSA Clearance in Ecuador, Advancing Latin American Expansion
27/07/2026
Clearance broadens access to hands-free, overground robotic gait training in Ecuador, and supports Wandercraft’s plans to expand advanced rehabilitation technology across Latin America NEW YORK and QUITO, Ecuador, July [...]
FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner
27/07/2026
Exclusive partnership provides 319 Golf Society members with preferred Flyte benefits. FLYTE brings its regional luxury private aviation platform to members of premier private golf clubs across the United States FORT [...]
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome
27/07/2026
Transaction to provide Oak Hill Bio with approximately $175 million in gross proceeds, including $75 million of cash in Research Alliance Corporation III’s (Nasdaq: RACC) (“RACC”) trust account that is fully backstopped [...]
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
27/07/2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, [...]
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
27/07/2026
Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero’s clinical leadership team as the Company advances SP001, a Phase 2-ready third- [...]
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
27/07/2026
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at multiple scientific [...]
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
27/07/2026
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based [...]
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
27/07/2026
— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process — — Topline data from Part A of Phase 2 ASCEND study remains on track for end of year — [...]
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
27/07/2026
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna [...]
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
27/07/2026
Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety [...]
Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs
27/07/2026
Reintroduction reflects clinician input and Curium investments to support reliable, long-term U.S. supply BOSTON, July 27, 2026 (GLOBE NEWSWIRE) -- Curium™ announced today the immediate reintroduction of Thallous [...]

Pages